Travere Therapeutics, Inc. (TVTX) has a negative trailing P/E of -54.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 128.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -1.84%, forward earnings yield 0.78%. PEG 1.31.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -14.6 | 0.11 | 2.28 | 5.24 | - |
| 2017 | -13.7 | -0.71 | 2.79 | 5.27 | - |
| 2018 | -8.9 | -0.14 | 2.87 | 5.57 | - |
| 2019 | -4.1 | -0.11 | 2.72 | 3.43 | - |
| 2020 | -7.6 | -2.65 | 6.13 | 6.53 | - |
| 2021 | -10.3 | 0.67 | 6.15 | 14.09 | - |
| 2022 | -4.8 | -0.11 | 31.29 | 12.25 | - |
| 2023 | -6.0 | 0.09 | 3.32 | 4.60 | - |
| 2024 | -4.3 | -0.02 | 23.26 | 5.89 | - |
| 2025 | -67.8 | 0.79 | 29.69 | 6.95 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.25 | $133.59M | $-47.9M | -35.9% |
| 2017 | $-1.54 | $154.94M | $-59.73M | -38.6% |
| 2018 | $-2.54 | $164.25M | $-102.68M | -62.5% |
| 2019 | $-3.46 | $175.34M | $-146.43M | -83.5% |
| 2020 | $-3.56 | $198.32M | $-169.43M | -85.4% |
| 2021 | $-3.01 | $227.49M | $-180.09M | -79.2% |
| 2022 | $-4.37 | $212.02M | $-278.48M | -131.3% |
| 2023 | $-1.50 | $145.24M | $-111.4M | -76.7% |
| 2024 | $-4.08 | $233.18M | $-321.55M | -137.9% |
| 2025 | $-0.56 | $490.73M | $-50.26M | -10.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.34 | $-6.79 – $11.30 | $692.21M | $624.28M – $752.38M | 9 |
| 2027 | $2.17 | $-0.56 – $4.80 | $926.94M | $781.52M – $1.06B | 8 |
| 2028 | $3.41 | $2.02 – $5.75 | $1.09B | $1.09B – $1.09B | 6 |
| 2029 | $4.07 | $3.23 – $5.12 | $1.31B | $1.1B – $1.57B | 4 |
| 2030 | $5.07 | $4.02 – $6.38 | $1.52B | $1.28B – $1.82B | 2 |
